How do I check that two SSA lots of semaglutide agree on content assay?

Setup, so nobody has to ask: SSA · semaglutide.

An unexpected observation, and I would like a differential rather than reassurance.

The conditions were within what I understood to be the acceptable range, which is why I am asking.

What is the most likely explanation, and how would I confirm it?

Put another way, batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

In practice, if the entire lot failed qualification, a retest on a different vial is sometimes done, but reporting a retest result under the same lot number is misleading.

The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

The sample size determination requires choosing a confidence level and an acceptable error rate, and the smaller the error rate you want, the larger your sample must be.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.

If testing multiple vials, state how many you tested and why you chose those vials.

edited 23 Dec 2024 by eoin_mcgarry — clarified the distinction between purity and content

The honest statement is that unless you have tested multiple vials or have segregation data, you are making an assumption about lot homogeneity that may not hold.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

Assume segregation is possible, and design your sampling to catch it if it exists.

The failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

Most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

Testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.